A private equity datapoint that might surprise you

DD readers will be well aware by now that private equity has had a good pandemic. Not only are the share prices of listed buyout groups at highs (we wrote about one consequence of that on Wednesday), but the pandemic’s hit to corporate valuations, particularly in the UK, has given private equity firms some opportunities to cinch cheaper deals. Read More...

Motley Fool

Why Intellia Therapeutics Was a Winner on Wednesday

Mere days after enjoying a major stock price pop, Intellia Therapeutics (NASDAQ: NTLA) had another good day on Wednesday. In a regulatory filing, the company wrote that, “We intend to use the net proceeds from this offering to advance the clinical development of our lead programs, other pipeline candidates and the continued investment in our modular platform as well as for working capital, and other general corporate purposes.” As of the end of March, it had approximately the same amount of cash, equivalents, and marketable securities on its books.

Read More